Timber Creek Capital Management LLC Grows Position in Elevance Health, Inc. $ELV

Timber Creek Capital Management LLC lifted its position in Elevance Health, Inc. (NYSE:ELV) by 32.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,652 shares of the company’s stock after acquiring an additional 4,034 shares during the quarter. Elevance Health makes up approximately 1.3% of Timber Creek Capital Management LLC’s portfolio, making the stock its 29th largest position. Timber Creek Capital Management LLC’s holdings in Elevance Health were worth $5,380,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Elevance Health by 94.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after acquiring an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. purchased a new position in Elevance Health in the second quarter valued at about $32,000. Physician Wealth Advisors Inc. increased its stake in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Activest Wealth Management lifted its stake in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares during the last quarter. Finally, Glass Jacobson Investment Advisors llc increased its position in Elevance Health by 400.0% in the second quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock worth $39,000 after buying an additional 80 shares during the last quarter. 89.24% of the stock is owned by institutional investors.

Elevance Health Price Performance

ELV opened at $346.49 on Tuesday. The stock has a 50-day moving average price of $352.53 and a 200-day moving average price of $332.74. The stock has a market capitalization of $76.47 billion, a P/E ratio of 13.79, a PEG ratio of 1.93 and a beta of 0.50. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. The ex-dividend date is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is presently 27.23%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ELV. Barclays decreased their price objective on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Weiss Ratings cut Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 2nd. Wolfe Research set a $425.00 target price on Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. TD Cowen reaffirmed a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Finally, UBS Group set a $400.00 price target on shares of Elevance Health in a report on Thursday, January 29th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $390.55.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.